Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curative Biotechnology Inc CUBT

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is... see more

Recent & Breaking News (OTCPK:CUBT)

Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

GlobeNewswire March 22, 2024

Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

GlobeNewswire January 8, 2024

Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors

GlobeNewswire October 31, 2023

Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions

GlobeNewswire June 6, 2023

Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation

GlobeNewswire May 24, 2023

Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study

GlobeNewswire January 5, 2023

Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange

GlobeNewswire September 27, 2022

Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors

GlobeNewswire June 16, 2022

Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors

PR Newswire May 12, 2022

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

GlobeNewswire May 12, 2022

Curative Biotechnology Announces Toxicology Studies Under Good Laboratory Practices (GLP) for Metformin Eye Drop Formulations for Treatment of Macular Degeneration

PR Newswire May 3, 2022

Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration

GlobeNewswire May 3, 2022

Curative Biotechnology Announces Cooperative Research and Development Agreement(CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration

PR Newswire March 21, 2022

Curative Biotechnology Announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration

GlobeNewswire March 21, 2022

[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

GlobeNewswire November 24, 2021

CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

GlobeNewswire November 24, 2021

CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO

GlobeNewswire October 12, 2021

CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE

GlobeNewswire October 7, 2021

Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine

PR Newswire October 7, 2021

Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board

GlobeNewswire September 2, 2021